Analysts Set NantHealth Inc (NH) Price Target at $8.05
NantHealth Inc (NASDAQ:NH) has been assigned an average recommendation of “Buy” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $8.05.
NH has been the subject of several research reports. BidaskClub cut shares of NantHealth from a “sell” rating to a “strong sell” rating in a research report on Tuesday, November 7th. Canaccord Genuity lowered their price target on shares of NantHealth from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Friday, November 17th. Finally, Zacks Investment Research raised shares of NantHealth from a “hold” rating to a “buy” rating and set a $4.00 price target for the company in a research report on Wednesday, November 22nd.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in NantHealth by 20.2% during the 2nd quarter. Vanguard Group Inc. now owns 423,537 shares of the company’s stock valued at $1,792,000 after purchasing an additional 71,087 shares in the last quarter. Highbridge Capital Management LLC increased its stake in NantHealth by 6.5% during the 3rd quarter. Highbridge Capital Management LLC now owns 250,000 shares of the company’s stock valued at $1,030,000 after purchasing an additional 15,264 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in NantHealth by 91.5% during the 2nd quarter. Goldman Sachs Group Inc. now owns 169,603 shares of the company’s stock valued at $717,000 after purchasing an additional 81,024 shares in the last quarter. Northern Trust Corp increased its stake in NantHealth by 133.9% during the 2nd quarter. Northern Trust Corp now owns 151,907 shares of the company’s stock valued at $643,000 after purchasing an additional 86,955 shares in the last quarter. Finally, Advisor Group Inc. acquired a new position in NantHealth during the 4th quarter valued at approximately $450,000. Hedge funds and other institutional investors own 6.27% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Analysts Set NantHealth Inc (NH) Price Target at $8.05” was published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2018/03/05/analysts-set-nanthealth-inc-nh-price-target-at-8-05.html.
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.